Adage Capital Partners Gp, L.L.C. Vaxcyte, Inc. Transaction History
Adage Capital Partners Gp, L.L.C.
- $52.3 Billion
- Q2 2024
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 85,088 shares of PCVX stock, worth $8.98 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
85,088
Previous 85,088
-0.0%
Holding current value
$8.98 Million
Previous $5.81 Million
10.53%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding PCVX
# of Institutions
290Shares Held
110MCall Options Held
248KPut Options Held
109K-
Black Rock Inc. New York, NY9.94MShares$1.05 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.8MShares$1.03 Billion0.01% of portfolio
-
Janus Henderson Group PLC London, X08.87MShares$936 Million0.37% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.2MShares$866 Million9.34% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$485 Million0.06% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $6.26B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...